Strata Oncology
The company said the results highlight precision oncology implementation challenges and its test's ability to help overcome these issues.
Strata Oncology Raises $90M in Series C Financing
The firm said it will use the proceeds to accelerate development of its MRD assay for early-stage cancers and its treatment selection tests for solid tumors.
Strata Oncology, Pfizer Partner to Explore New Biomarker Indications for FDA-Approved Drugs
Pfizer is the first drugmaker to join the Strata PATH platform trial and will contribute drugs to advanced cancer patients in four study arms.
Strata Oncology Receives Medicare Coverage for NGS Test
The test assesses multiple factors, including single-/multi-nucleotide variants, short insertions and deletions, and microsatellite instability status.